Cargando…

Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort

BACKGROUND: Metastatic breast cancer (MBC) behaviour differs depending on hormone receptors (HR) and human epidermal growth factor receptor (HER2) statuses. METHODS: The kinetics of central nervous system (CNS) metastases (CNS metastasis-free survival, CNSM-FS) and subsequent patient’s prognosis (ov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Darlix, Amélie, Louvel, Guillaume, Fraisse, Julien, Jacot, William, Brain, Etienne, Debled, Marc, Mouret-Reynier, Marie Ange, Goncalves, Anthony, Dalenc, Florence, Delaloge, Suzette, Campone, Mario, Augereau, Paule, Ferrero, Jean Marc, Levy, Christelle, Fumet, Jean-David, Lecouillard, Isabelle, Cottu, Paul, Petit, Thierry, Uwer, Lionel, Jouannaud, Christelle, Leheurteur, Marianne, Dieras, Véronique, Robain, Mathieu, Chevrot, Michaël, Pasquier, David, Bachelot, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964671/ https://www.ncbi.nlm.nih.gov/pubmed/31719684 http://dx.doi.org/10.1038/s41416-019-0619-y

Ejemplares similares

Impact of body mass index on overall survival in patients with metastatic breast cancer
por: Saleh, Khalil, et al.
Publicado: (2020)

Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database
por: Carausu, M., et al.
Publicado: (2021)

Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database
por: Carausu, Marcela, et al.
Publicado: (2022)

Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort
por: Grinda, T., et al.
Publicado: (2021)

Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort
por: Moinard-Butot, Fabien, et al.
Publicado: (2022)

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
por: Le Du, Fanny, et al.
Publicado: (2023)

Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort
por: Frank, Sophie, et al.
Publicado: (2020)

Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study
por: François-Martin, Hélène, et al.
Publicado: (2023)

Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME)
por: Sirieix, Junien, et al.
Publicado: (2020)

Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France
por: de Calbiac, Ombline, et al.
Publicado: (2022)

Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real‐world database
por: Mailliez, Audrey, et al.
Publicado: (2022)

Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program
por: Cabel, Luc, et al.
Publicado: (2021)

Real-world evidence of the management and prognosis of young women (⩽40 years) with de novo metastatic breast cancer
por: Mallet, Amélie, et al.
Publicado: (2022)

Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study
por: Vasseur, Antoine, et al.
Publicado: (2022)

Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer
por: Bortolini Silveira, Amanda, et al.
Publicado: (2021)

Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes
por: Carausu, Marcela, et al.
Publicado: (2022)

CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database
por: Gougis, P., et al.
Publicado: (2019)

Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study
por: Bidard, François-Clément, et al.
Publicado: (2012)

Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database
por: Annonay, Mylène, et al.
Publicado: (2021)

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis
por: Lefebvre, Celine, et al.
Publicado: (2016)

Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials
por: Lerebours, Florence, et al.
Publicado: (2020)

Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program
por: Bertho, Marion, et al.
Publicado: (2021)

COVID-19 et personnes suivies pour un cancer du sein : recommandations françaises pour la pratique clinique de Nice-St Paul de Vence, en collaboration avec le Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), la Société d’Imagerie de la Femme (SIFEM), la Société Française de Chirurgie Oncologique (SFCO), la Société Française de Sénologie et Pathologie Mammaire (SFSPM) et le French Breast Cancer Intergroup-UNICANCER (UCBG)
por: Gligorov, Joseph, et al.
Publicado: (2020)

Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2–14)
por: Penault-Llorca, Frédérique, et al.
Publicado: (2019)

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
por: Jacot, William, et al.
Publicado: (2019)

Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database
por: Courtinard, Coralie, et al.
Publicado: (2023)

Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer
por: Quenel-Tueux, Nathalie, et al.
Publicado: (2015)

Multicenter evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic
por: Bizot, Alexandra, et al.
Publicado: (2021)

Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study
por: Coudert, Bruno, et al.
Publicado: (2020)

Breaking down barriers in morning glories
por: Field, David L., et al.
Publicado: (2019)

Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications
por: Jézéquel, Pascal, et al.
Publicado: (2019)

Factors associated with enrolment in clinical trials among women with early-stage breast cancer
por: Presti, D., et al.
Publicado: (2022)

Target trial emulation to assess real-world efficacy in the Epidemiological Strategy and Medical Economics metastatic breast cancer cohort
por: Antoine, Alison, et al.
Publicado: (2023)

Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer
por: Delrieu, Lidia, et al.
Publicado: (2020)

The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME)
por: Pérol, David, et al.
Publicado: (2019)

VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study
por: Gal, Jocelyn, et al.
Publicado: (2020)

Addressing the issue of bias in observational studies: Using instrumental variables and a quasi-randomization trial in an ESME research project
por: Ezzalfani, Monia, et al.
Publicado: (2021)

Pleiotropy Modulates the Efficacy of Selection in Drosophila melanogaster
por: Fraïsse, Christelle, et al.
Publicado: (2019)

Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients
por: Jobard, Elodie, et al.
Publicado: (2017)

Effectiveness of a Global Multidisciplinary Supportive and Educational Intervention in Thermal Resort on Anthropometric and Biological Parameters, and the Disease-Free Survival after Breast Cancer Treatment Completion (PACThe)
por: Vasson, Marie-Paule, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hitap4jjnlsd30g0di95besp0d